
    
      This will be a phase III, randomized, multicentre, open-label, concentration-controlled study
      in subjects undergoing a first or second renal transplant, with induction immunosuppression
      with an IL-2 receptor antibody (basiliximab), mycophenolate mofetil and steroids.

      The primary endpoint to assess non-inferiority will be efficacy failure at the end of Month
      12 after randomization.
    
  